GLP-1s as a structural healthcare disruptor
The GLP-1 drug class represents a structural shift in global healthcare due to its wide-ranging metabolic, cardiovascular, and potential cognitive benefits.
The argument
The guest characterized GLP-1s as the closest thing to a 'magic pill' the industry has developed, noting that their ability to address obesity upstream has cascading positive effects on blood pressure, lipid profiles, and cancer rates.
The thesis, stress-tested
✓ What validates it
- ✓Clinical data confirming cognitive/dementia benefits for GLP-1s
- ✓Widespread commercial adoption of high-dose oral formulations
▸ Risks discussed
- ▸Short-term GI side effects (nausea/vomiting) during the first 30 days of treatment
- ▸High cost and payer reimbursement hurdles
Hear it yourself
"If GLP ones actually do eliminate some of that those chronic issues, where does that leave us then for is it is there as much health care as we need then if we're kinda gotten better at the the very upstream part of it? So the GLP one drug class is probably the closest thing I've ever seen to a magic pill that the industry has developed."
00:00 / 00:30
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE